DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of “Hold” by Analysts

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have received an average rating of “Hold” from the fifteen research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $13.3846.

Several analysts recently commented on XRAY shares. Weiss Ratings restated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Citigroup started coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective on the stock. Piper Sandler increased their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. BMO Capital Markets reissued a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Finally, Mizuho lowered their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th.

Insider Activity at DENTSPLY SIRONA

In other news, Director Brian P. Mckeon bought 10,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian T. Gladden purchased 9,985 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. This represents a 19.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 35,160 shares of company stock valued at $351,179. Insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently added to or reduced their stakes in XRAY. BlackRock Inc. bought a new position in DENTSPLY SIRONA during the second quarter valued at approximately $283,405,000. Southpoint Capital Advisors LP bought a new stake in DENTSPLY SIRONA in the first quarter worth approximately $116,000,000. AQR Capital Management LLC grew its position in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Armistice Capital LLC increased its stake in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $47,780,000. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Stock Down 1.8%

NASDAQ:XRAY opened at $11.40 on Friday. The business’s fifty day moving average price is $11.88 and its 200 day moving average price is $11.87. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -4.15, a PEG ratio of 1.39 and a beta of 0.85. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA has a 1-year low of $9.40 and a 1-year high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The firm had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. During the same period last year, the company posted $0.52 EPS. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts forecast that DENTSPLY SIRONA will post 1.48 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.